Prenylation of rab6a as a potency assay for choroideremia gene therapy
Choroideremia (CHM) is a rare, X-linked recessive retinal dystrophy caused by mutations in the CHM gene. This gene encodes for Rab escort protein 1 (REP1), which is ubiquitously expressed in human cells and plays a key role in intracellular trafficking through the prenylation of RabGTPases. Deficien...
Main Authors: | Patricio, M, Barnard, A, MacLaren, R |
---|---|
Format: | Conference item |
Published: |
Elsevier
2017
|
Similar Items
-
The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
by: Patrício, M, et al.
Published: (2018) -
Choroideremia: molecular mechanisms and development of AAV gene therapy
by: Patrício, M, et al.
Published: (2018) -
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
by: Xue, K, et al.
Published: (2018) -
Visual acuity after retinal gene therapy for Choroideremia
by: Edwards, T, et al.
Published: (2016) -
Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.
by: Barnard, A, et al.
Published: (2014)